Inhibition of Corneal Neovascularization by Topically Administered Propranolol in A Rabbit Model
暂无分享,去创建一个
[1] H. Önder,et al. The effect of β receptor blockade through propranolol on corneal neovascularization. , 2014, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[2] E. Masini,et al. Pharmacokinetics and local safety profile of propranolol eye drops in rabbits , 2014, Pediatric Research.
[3] Yasin Cinar,et al. Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model , 2014, Cutaneous and ocular toxicology.
[4] H. Tchah,et al. Topically administered bevacizumab had longer standing anti-angiogenic effect than subconjunctivally injected bevacizumab in rat corneal neovacularization. , 2013, International journal of ophthalmology.
[5] P. Bagnoli,et al. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. , 2013, Experimental eye research.
[6] N. Lee,et al. Inhibition of Corneal Neovascularization by Subconjunctival and Topical Bevacizumab and Sunitinib in a Rabbit Model , 2013, Cornea.
[7] R. Erdoğan. Comparison of subconjunctivally injected bevacizumab , ranibizumab , and pegaptanib for inhibition of corneal neovascularization in a rat model 窑 , 2013 .
[8] J. Pérez-Santonja,et al. [Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model]. , 2013, Archivos de la Sociedad Espanola de Oftalmologia.
[9] D. Azar,et al. Corneal neovascularization: an anti-VEGF therapy review. , 2012, Survey of ophthalmology.
[10] A. Karalezli,et al. Topical and Subconjunctival Bevacizumab for Corneal Neovascularization in an Experimental Rat Model , 2012, Ophthalmic Research.
[11] U. Keklikçi,et al. The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.
[12] R. Dana,et al. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). , 2012, The ocular surface.
[13] H. Hosseini,et al. Anti-VEGF Therapy With Bevacizumab for Anterior Segment Eye Disease , 2012, Cornea.
[14] Terry Kim,et al. Anatomy and physiology of the cornea , 2011, Journal of cataract and refractive surgery.
[15] Hadi Z-Mehrjardi,et al. Prevention of Corneal Neovascularization: Comparison of Different Doses of Subconjunctival Bevacizumab with Its Topical Form in Experimental Rats , 2011, Ophthalmic Research.
[16] P. Fortunato,et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. , 2011, Investigative ophthalmology & visual science.
[17] J. Alió,et al. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model. , 2010, American journal of ophthalmology.
[18] Terry Kim,et al. Inhibition of Experimental Corneal Neovascularization by Using Subconjunctival Injection of Bevacizumab (Avastin) , 2008, Cornea.
[19] 김태임,et al. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). , 2008 .
[20] R. Simó,et al. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. , 2006, Current diabetes reviews.
[21] V. Bhalla,et al. inhibition in , 2005 .
[22] Christopher J. Robinson,et al. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.
[23] D. Azar,et al. Corneal neovascularization. , 2001, Current opinion in ophthalmology.
[24] A. Adamis,et al. Ocular neovascularization: an epidemiologic review. , 1998, Survey of ophthalmology.